Technical Analysis for TCRT - Alaunos Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.12 | -8.94% | -0.11 |
TCRT closed down 8.94 percent on Friday, April 19, 2024, on 61 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 8
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New Downtrend | Bearish | -8.94% | |
| Spinning Top | Other | -8.94% |
| Alert | Time |
|---|---|
| Down 5% | about 15 hours ago |
| Down 3% | about 15 hours ago |
| Fell Below Previous Day's Low | about 15 hours ago |
| 60 Minute Opening Range Breakdown | about 16 hours ago |
| Down 2 % | about 16 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, targeting common tumor-related mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Cell Therapy Epidermal Growth Factor Receptor Oncogenes National Cancer Institute P53 Tumor Suppressor Genes Mm 151 Ras Gtpase University Of Texas Md Anderson Cancer Center
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Cell Therapy Epidermal Growth Factor Receptor Oncogenes National Cancer Institute P53 Tumor Suppressor Genes Mm 151 Ras Gtpase University Of Texas Md Anderson Cancer Center
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.47 |
| 52 Week Low | 0.6615 |
| Average Volume | 80,958 |
| 200-Day Moving Average | 2.39 |
| 50-Day Moving Average | 1.79 |
| 20-Day Moving Average | 1.64 |
| 10-Day Moving Average | 1.47 |
| Average True Range | 0.16 |
| RSI (14) | 23.08 |
| ADX | 27.47 |
| +DI | 8.11 |
| -DI | 31.73 |
| Chandelier Exit (Long, 3 ATRs) | 1.54 |
| Chandelier Exit (Short, 3 ATRs) | 1.59 |
| Upper Bollinger Bands | 2.12 |
| Lower Bollinger Band | 1.16 |
| Percent B (%b) | -0.05 |
| BandWidth | 58.17 |
| MACD Line | -0.16 |
| MACD Signal Line | -0.10 |
| MACD Histogram | -0.0596 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.36 | ||||
| Resistance 3 (R3) | 1.38 | 1.32 | 1.32 | ||
| Resistance 2 (R2) | 1.32 | 1.26 | 1.31 | 1.31 | |
| Resistance 1 (R1) | 1.22 | 1.22 | 1.19 | 1.20 | 1.29 |
| Pivot Point | 1.16 | 1.16 | 1.15 | 1.15 | 1.16 |
| Support 1 (S1) | 1.06 | 1.10 | 1.03 | 1.04 | 0.95 |
| Support 2 (S2) | 1.00 | 1.06 | 0.99 | 0.93 | |
| Support 3 (S3) | 0.90 | 1.00 | 0.92 | ||
| Support 4 (S4) | 0.88 |
